solid pt acceler
see growth acceler introduc estim
report in-lin howev share trade unch
think market react book bill ex-passthrough deceler
prior year tough comp notwithstand view
book strong in-lin peer report importantli
though rais revenu expect follow result
coverag ntm revenu vs ntm backlog
y/i moreov see momentum improv expect overal y/i revenu
growth acceler
highlight quarter execut pretti consist revenu
exceed expect modestli term mix ta csm
exceed growth expect quarter ta benefit
acceler technolog deploy real world evid engag
csm demonstr turnaround view success
integr commerci oper highlight quarter
top client pharma oce win us anoth top pharma win
asia among new oce deal announc think larg pharma
win demonstr competit potenti oce offer revenue
littl shi expect though think quarterli nois driven
time perhap cancel ntm backlog
impli coverag estim
updat model introduc estim though updat
revenu mix much chang estim growth bp
lower bp higher ep
penni chang ep introduc revenu
impli y/i growth associ ep
impli growth y/i
pt pt driven introduc ep
estim impli price-to-earnings multipl target
strength real world client engag
acceler tech deploy
improv ntm backlog suggest
success integr cmsc
tr target
page
share upsid current strh factsetstrh pt low/high rangesourc factset strh research ia hold inc
page
sandi draper statement dollar y/i total gross depreci restructur merger related- impair oper fit incl restruc net interest expens incom incom incom tax tax equiti unconsolid equiti earn unconsolid net net loss incom attribut non-controlling net incom attribut dilut dilut share forma adjust net adj pre-tax tax non-gaap net non-gaap growth forma adjust ebitdaadjust margin robinson humphrey research estimatestick iqva
iqvia largest cro revenu oper countri employe
compani found headquart durham nc compani formerli quintil
merg im health combin entiti iqvia oper three segment commerci
solut data technolog drive real world evid use life sceinc client clinic
trial integr healthcar servic contract sale compris
respect sale iqvia first went public taken privat privat equiti
went public acquir im health
buy rate base view ebitda growth exceed revenu growth due
oper leverag cost synergi recognit expect manag reinforc oper
perform share repurchas expect contribut mid-teen ep growth
also think acquir im busi may benefit multipl expans mid-cap peer
technolog servic space given acquisit im
valuat risk
pt assign probabl low case price-to-earnings stock mid case
high case pt impli price-to-earnings multipl
ep estim ahead peer averag ntm multipl justifi view
given peer lead book perform anticip acceler revenu growth one
leader ep growth well view investor begin compar mid/
larg cap high visibl growth compani typic trade pe low- mid-
risk rate price target
continu cancel late stage busi net book bill remain target
merger synergi fail materi custom attrit due im merger
sandi draper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
